Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS228CN in amyotrophic lateral sclerosis
NCT07118319Phase 1Recruiting
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Neural Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of XS228 in amyotrophic lateral sclerosis (ALS) (2 arms). Primary endpoint: Adverse Events and Serious Adverse Events at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
XS228
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07118319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118319.